Aesica Pharmaceuticals
CDMO for APIs & finished dosage forms | Aesica.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
$374m Valuation: $374m 17.5x EV/Revenue -65.9x EV/EBITDA | Acquisition | ||
| Total Funding | 000k | ||
| GBP | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (33 %) | 31 % | 12 % | 13 % | (41 %) | (27 %) | (55 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 20 % | 15 % | 8 % | 11 % | (10 %) | (96 %) | (454 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 20 % | 55 % | 29 % | (5 %) | 46 % | 13 % | (479 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Aesica Pharmaceuticals, a part of Recipharm, is a leading global Contract Development and Manufacturing Organization (CDMO) specializing in the pharmaceutical industry. The company offers a wide range of services including drug development, manufacturing, and packaging solutions to pharmaceutical companies worldwide. Aesica serves clients ranging from small biotech firms to large pharmaceutical corporations, operating in a highly competitive and regulated market.
The business model of Aesica revolves around providing end-to-end solutions for the pharmaceutical lifecycle, from initial development through to commercial manufacturing and packaging. This integrated approach allows clients to streamline their supply chains and reduce time-to-market for new drugs. Aesica generates revenue through long-term contracts and project-based engagements, ensuring a steady income stream while fostering strong client relationships.
Aesica's market position is bolstered by its commitment to quality, regulatory compliance, and innovation. The company continuously invests in state-of-the-art facilities and cutting-edge technologies to meet the evolving needs of the pharmaceutical industry. With a global footprint and a diverse portfolio of services, Aesica is well-positioned to capitalize on the growing demand for outsourced pharmaceutical development and manufacturing services.
Keywords: CDMO, pharmaceutical manufacturing, drug development, packaging solutions, biotech, regulatory compliance, innovation, global footprint, supply chain, long-term contracts.